$0.59
-0.05 (-7.51%)
Open$0.65
Previous Close$0.63
Day High$0.65
Day Low$0.56
52W High$3.07
52W Low$0.53
Volume—
Avg Volume4.41M
Market Cap165.95M
P/E Ratio—
EPS$-0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+3,565.5% upside
Current
$0.59
$0.59
Target
$21.48
$21.48
$15.01
$21.48 avg
$34.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 87.85M | 178.19M | 160.29M |
| Net Income | -86,316,223 | 4.92M | 3.11M |
| Profit Margin | -98.3% | 2.8% | 1.9% |
| EBITDA | -90,110,965 | 6.39M | 5.91M |
| Free Cash Flow | — | 2.75M | 2.88M |
| Rev Growth | — | +11.2% | +5.5% |
| Debt/Equity | — | 0.18 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |